What is Exelixis's 12 months or more?

Exelixis (EXEL) reported 12 months or more of $7.94M in Q1 2026.

How has Exelixis's 12 months or more changed year-over-year?

Exelixis's 12 months or more decreased by 95.4% year-over-year, from $171.78M to $7.94M.

What is the long-term trend for Exelixis's 12 months or more?

Over 3 years (2022 to 2025), Exelixis's 12 months or more has grown at a -65.1% compound annual growth rate (CAGR), from $237.6M to $10.1M.

Exelixis EXEL 12 months or more

12 months or more at other companies

Ionis PharmaceuticalsIONS

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

See full

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's 12 months or more.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's 12 months or more?: Exelixis (EXEL) reported 12 months or more of $7.94M in Q1 2026.
How has Exelixis's 12 months or more changed year-over-year?: Exelixis's 12 months or more decreased by 95.4% year-over-year, from $171.78M to $7.94M.
What is the long-term trend for Exelixis's 12 months or more?: Over 3 years (2022 to 2025), Exelixis's 12 months or more has grown at a -65.1% compound annual growth rate (CAGR), from $237.6M to $10.1M.